The University of California-led party can still appeal the decision from the US Patent and Trademark Office, but it has been dealt a major setback.
The companies will work together to create an end-to-end workflow for biomarker and drug target validation, and assay development.
Under a new co-exclusive agreement, Thermo Fisher will be able to sell 908's ZipChip platform alongside its HRAM mass spec instruments.
A genome-wide association study involving more than 52,000 men led to variants linked to male pattern baldness, along with early SNP-based attempts to predict the trait.
The company plans to use the funds to support the worldwide launch of its commercial platform for propagation and gene editing in cell types that are difficult to transfect.
The test analyzes the mitochondrial genome to determine which men with clinical suspicion of prostate cancer are likely to have high-grade disease.
The firm's diagnostics revenues grew 8 percent year over year, and it beat the consensus Wall Street estimates on the top and bottom lines.
Hologic said that HCV therapeutic options are evolving rapidly, and the approval will enable physicians to quickly decide on the best treatments.
Researchers profiling pancreatic neuroendocrine tumors detected inherited cancer-related mutations in nearly one-fifth of affected individuals.
The company said it will use the proceeds of the financing round to accelerate commercial adoption of its NGS-based personalized cancer treatment test.
The funds will support development of the company's mammalian display antibody technology, which it says could aid applications including biopharma research.
The firm's growth in China and pharmaceutical end markets help it beat the Wall Street estimate for revenue and EPS, despite currency headwinds.
The tests are twice as fast as the firm's Xpert line and run on Cepheid's flagship GeneXpert system.
The company beat the consensus Wall Street estimate for the fourth quarter on the bottom line but missed the estimate on the top line.
The preliminary revenue results come ahead of the company's planned merger with Takara Bio USA Holdings.
Both companies plan to offer the test to researchers and clinicians to help better determine when a patient can be diagnosed with an infectious disease.
Synthetic lipids developer Anatrace said the addition of Molecular Dimensions' products to its menu will add to its array of drug discovery tools.
The company said investors have agreed to purchase $5.6 million of common stock as well as warrants that, if exercised, could raise an additional $5.1 million.
The new filing comes after the firm recently withdrew plans last month to raise $8 million.
Privately held Miragen will pick up Signal's Nasdaq listing, and the combined company is scheduled to begin trading today.
The companies will work together to seek FDA clearance or approval for a number of biomarker and immuno-oncology assay kits for use on the MiSeqDx.
Under the deal, the parties will provide Perthera's Precision Cancer Analysis molecular profiling service to Hope for Stomach Cancer patients free of charge.
The companies will study the combination of their respective technologies for predicting patient responses to metastatic lung cancer immunotherapy.
The company said its product revenues rose during the fourth quarter thanks to an increase in T2Candida panel sales due to increased patient testing.
The company reported revenues of $470.3 million, down from $478.2 million in Q4 2015 but beating the average analysts' estimate of $464.5 million.
Startup companies are taking on personalized medicine, CNET reports.
Bruce Booth writes at Life Sci VC that biotech clusters like Boston and San Francisco are getting even more consolidated.
The Verge speaks with Mark and Scott Kelly, who are the subjects of NASA's Twin Study.
In Genome Biology this week: genes linked to Hirschsprung disease, structural variant patterns in autism, and more.